Belatacept as maintenance therapy in kidney transplant recipients with ANCA-associated vasculitis

Sir,

Kidney transplantation (KT) is considered the best kidney replacement therapy (KRT) modality in eligible patients with end-stage kidney disease (ESKD), including antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitides (AAV) induced ESKD. Anti-rejection therapy usually consists in a combination of calcineurin inhibitor (CNI) and mycophenolate mofetil (MMF). For a decade, a novel immunomodulatory agent targeting T-cell co-stimulation, belatacept, has been increasingly used (1). Herein, we report a series of 6 KT recipients with AAV who received belatacept.

**Patient 1.** A 24-year-old woman with anti-myeloperoxidase (anti-MPO) positive microscopic polyangiitis (MPA) received a first kidney transplant. Six months post-KT, CNI was converted to belatacept because of CNI-induced vascular lesions. Four years after the conversion, the immunosuppressive regimen was changed to a CNI-azathioprine combination in the hope of a pregnancy.

**Patient 2.** A 33-year-old woman with anti-MPO positive MPA received a first kidney transplant. Belatacept was part of her initial anti-rejection regimen. At last follow-up, 3 years post-KT, she had experienced neither graft rejection nor AAV relapse.

**Patient 3.** A 44-year-old man with anti-proteinase 3 (anti-PR3) positive granulomatosis with polyangiitis (GPA) received a first kidney transplant. Belatacept was part of his initial anti-rejection regimen. He experienced neither graft rejection nor AAV relapse during the follow-up but ocular toxoplasmosis 10 years post-transplantation leading to the withdrawal of belatacept which could not prevent a fatal outcome.

**Patient 5.** A 66-year-old man with anti-MPO-positive MPA received a first kidney transplant. His initial anti-rejection maintenance therapy consisted in steroids, CNI and mechanistic target of rapamycin inhibitor (mTORi). He was converted to a belatacept-MMF combination within a month post-KT. One year after belatacept initiation, the patient had experienced neither graft rejection, nor AAV relapse.

**Patient 6.** A 39-year-old man with anti-MPO-positive MPA received a first kidney transplant. ANCA were still positive 6 months later, he was diagnosed with an AAV renal relapse, treated with rituximab for induction and converted back to a CNI-MMF combination. Six months later, the ANCA titre decreased but SCR and proteinuria remained elevated. However, indication for graft biopsy to assess AAV residual renal activity was considered futile. Indeed, it was decided that immunosuppression would not be intensified because of recent neoplastic complications.

**Patient 4.** A 63-year-old man with anti-proteinase 3 (anti-PR3) positive granulomatosis with polyangiitis (GPA) received a first kidney transplant. Belatacept was part of his initial anti-rejection regimen. He experienced neither graft rejection nor AAV relapse during the follow-up but ocular toxoplasmosis 10 years post-transplantation leading to the withdrawal of belatacept which could not prevent a fatal outcome.

In the present series (Table 1), one patient out of 6 (17%) presented an AAV relapse while under belatacept roughly corresponding to a relapse rate of 0.05 per patient year. Usually, the AAV relapse rate in KTRs is estimated to be below 0.03 per patient-year (2-6), although guidelines do not consider CNI or MMF as first-line maintenance therapies in AAV (7-9). On the other hand, co-stimulation blockade has been tested in non-severe relapsing granulomatosis with polyangiitis (Wegener’s) without raising any efficacy or safety concern (10) and MMF may be used in patients with contraindication to azathioprine, rituximab or methotrexate (7). Therefore, one may hypothesize that a belatacept-MMF combination may fare well regarding the risk of relapse of AAV in KTRs although, the small number of patients in the present series precludes any conclusion. However, it most importantly draws the attention on the lack of data regarding the risk of relapse after KT with belatacept and could conversely renew the interest of co-stimulation blockade in AAV.

**Table 1.** Demographics and characteristics of the patients converted to belatacept.

<table>
<thead>
<tr>
<th>Sex</th>
<th>Age at KT (years)</th>
<th>ANCA type</th>
<th>AAV phenotype</th>
<th>Time from last AAV relapse to KT</th>
<th>Treatment of last pre-KT AAV relapse (Induction/Maintenance)</th>
<th>ANCA at KT</th>
<th>Initial anti-rejection therapy (Induction/Maintenance)</th>
<th>Time from KT to belatacept initiation</th>
<th>Time from belatacept initiation to AAV relapse</th>
<th>Duration of belatacept exposure</th>
</tr>
</thead>
<tbody>
<tr>
<td>F</td>
<td>24</td>
<td>MPO</td>
<td>MPA</td>
<td>77</td>
<td>Steroids-RTX/MMF</td>
<td>negative</td>
<td>Basiliximab/Stereoids-CNI-MMF</td>
<td>5</td>
<td>-</td>
<td>48</td>
</tr>
<tr>
<td>F</td>
<td>33</td>
<td>MPO</td>
<td>MPA</td>
<td>34</td>
<td>Steroids-RTX/RTX</td>
<td>negative</td>
<td>Thymoglobulin/Stereoids-Belatacept-MMF</td>
<td>0</td>
<td>-</td>
<td>43</td>
</tr>
<tr>
<td>M</td>
<td>47</td>
<td>MPO</td>
<td>MPA</td>
<td>31</td>
<td>Steroids-PE-oral CYC/MMF</td>
<td>positive</td>
<td>Basiliximab/Stereoids-CNI-MMF</td>
<td>37</td>
<td>7</td>
<td>6</td>
</tr>
<tr>
<td>M</td>
<td>63</td>
<td>PR3</td>
<td>GPA</td>
<td>60</td>
<td>Steroids-JV CYC/ND</td>
<td>negative</td>
<td>Basiliximab/Stereoids-Belatacept-MMF</td>
<td>0</td>
<td>-</td>
<td>123</td>
</tr>
<tr>
<td>M</td>
<td>66</td>
<td>MPO</td>
<td>MPA</td>
<td>35</td>
<td>Steroids-RTX/RTX</td>
<td>negative</td>
<td>Basiliximab/Stereoids-MMF-mTOR inhibitor</td>
<td>0.5</td>
<td>-</td>
<td>23</td>
</tr>
<tr>
<td>M</td>
<td>39</td>
<td>MPO</td>
<td>MPA</td>
<td>10</td>
<td>Steroid-JV CYC/AZA converted to RTX</td>
<td>positive</td>
<td>Basiliximab/Stereoids-CNI-MMF</td>
<td>11</td>
<td>-</td>
<td>9</td>
</tr>
</tbody>
</table>


Clinical and Experimental Rheumatology 2021

Letters to the Editors
Service de Néphrologie et de Transplantation d’Organes, CHU Toulouse;
Service de Néphrologie et Transplantation Adulte, Hôpital Necker-Enfants Malades, Université de Paris, Assistance Publique-Hôpitaux de Paris, France.

Please address correspondence to:
Dr. Jonathan Chemouny,
Service de Néphrologie, CHU de Rennes,
Hôpital Pontchaillou, 2 rue Henri Le Guilloux, 35033 Rennes, France.
E-mail: jonathan.chemouny@chu-rennes.fr

Competing interests: D. Anglicheau reports personal fees for consultancies with Bristol Myers Squibb. All other authors declare no competing interests.

References